Press ESC to close

Peptide Lab App Log in Articles News Guide Products
More Peptide Tracker Calculator Best Calculators Peptide Statistics Contact Newsletter
Français English Deutsch Español Português العربية Italiano Polski 한국어 日本語 中文 Русский Nederlands Čeština Svenska Türkçe
SS-31
Elamipretide

SS-31 (élamipretide)

D-arginyl-2',6'-dimethyl-L-tyrosyl-L-lysyl-L-phenylalaninamide (elamipretide, MTP-131, Bendavia)

639.80 g/mol Molecular weight
C₃₂H₄₉N₉O₅ Molecular formula
Granted FDA accelerated approval in Barth syndrome (2025); under study in other indications Status
D-Arg-Dmt-Lys-Phe-NH₂ (aromatic-cationic tetrapeptide, alternating basic and aromatic residues)
Updated on November 7, 2026
SS-31 (élamipretide) Photo: Mikhail Nilov

What is SS-31 (elamipretide)?

SS-31, also known as elamipretide, MTP-131 and Bendavia, is a synthetic tetrapeptide designed to concentrate in the inner mitochondrial membrane. Its sequence, D-Arg-Dmt-Lys-Phe-NH₂, alternates positively charged residues (arginine, lysine) with aromatic residues (2',6'-dimethyltyrosine, phenylalanine). That alternation, the hallmark of the aromatic-cationic peptide family developed out of the work of Hazel Szeto and Peter Schiller (hence the SS abbreviation), lets it cross cell membranes without a dedicated transporter.

Its molecular weight is 639.80 g/mol, with a molecular formula of C₃₂H₄₉N₉O₅. The presence of a D-form arginine and of a non-natural dimethyltyrosine residue makes it markedly more resistant to peptidases than most linear peptides built only from L amino acids, which partly explains its clinically usable half-life.

What sets SS-31 apart from the vast majority of peptides discussed in research circles is simple: it is not a molecule known only through cell or rodent experiments. Elamipretide has been evaluated in several controlled human clinical trials, published in peer-reviewed journals, with positive results in some contexts and negative results in others. That dual reading is essential, and it shapes the rest of this guide.

The peptide was developed by Stealth BioTherapeutics and was the subject of a clinical program spanning rare mitochondrial diseases, heart failure, primary mitochondrial myopathy and degenerative ophthalmic conditions. All of these indications share a common hypothesis: when mitochondrial energy production is failing, stabilizing the architecture of the inner membrane might restore part of the affected organ's function.

Disclaimer. This content is provided for informational and educational purposes. It does not constitute medical advice, describes no protocol of use and must not serve as the basis for a health decision. Any question about a mitochondrial disease or a medicine should be directed to a qualified healthcare professional.

How does SS-31 act on the mitochondrion?

The identified molecular target of SS-31 is cardiolipin, a phospholipid with four fatty acid chains present almost exclusively in the inner mitochondrial membrane. Cardiolipin plays a major structural role: it contributes to the curvature of mitochondrial cristae, to the assembly of respiratory chain complexes into supercomplexes and to the anchoring of proteins such as cytochrome c.

Work by Birk and colleagues, published in the Journal of the American Society of Nephrology in 2013, showed that SS-31 binds cardiolipin with high affinity and protects mitochondrial cristae in a model of ischemia. That finding reoriented how the peptide is understood: initially described as a scavenger of reactive oxygen species, it is today described first and foremost as a modulator of the inner mitochondrial membrane.

More recent biophysical analyses refine this mechanism. SS-31 associates with cardiolipin-rich bilayers through a combination of electrostatic and hydrophobic interactions, and alters the membrane's surface electrostatic potential. That alteration influences how cardiolipin-dependent proteins organize and interact. A 2025 review published in Biomedicine & Pharmacotherapy by Sabbah and colleagues sums up this shift in paradigm: the antioxidant effect observed would largely be a consequence of better coupling of oxidative phosphorylation, rather than the primary cause of the peptide's action.

Several functional consequences have been reported in experimental systems: more efficient electron transfer, reduced electron leak that generates reactive species, limitation of the peroxidase activity of the cytochrome c/cardiolipin complex, and improved ATP synthesis in struggling mitochondria. One point recurs often in the literature: the effect appears weak or absent in already healthy mitochondria, which suggests a mechanism of restoration rather than stimulation.

Keep in mind that most of these observations come from isolated mitochondria, cell cultures or animal models. They explain why the peptide was tested in humans, but on their own they do not demonstrate a clinical benefit.

What is its regulatory status today?

On September 19, 2025, the FDA granted accelerated approval to elamipretide hydrochloride under the brand name FORZINITY, developed by Stealth BioTherapeutics. The approved indication is precise and narrow: to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. It is the first therapy authorized in this ultra-rare genetic disease, and the first medicine directly targeting the mitochondrion to obtain an FDA approval.

The nature of this approval is worth understanding. An accelerated approval is granted on the basis of a surrogate endpoint reasonably likely to predict clinical benefit. Here, that endpoint is improvement in knee extensor strength. Maintaining the authorization depends on later confirmation of clinical benefit in dedicated trials. An accelerated approval is therefore not equivalent to a definitive demonstration of long-term efficacy.

This decision concerns Barth syndrome only. It validates elamipretide in no other indication: not primary mitochondrial myopathy, not heart failure, not retinal disease and, still less, use in healthy people for performance or longevity purposes. Those uses remain outside the approved framework.

In Europe, no equivalent marketing authorization could be documented at the time of writing. The regulatory status of a single molecule can differ substantially from one jurisdiction to another, and it changes over time. If legal status or reimbursement affects you directly, check with the competent national agency rather than with a reseller.

Finally, there is a clear distinction between an approved medicine, manufactured to pharmaceutical good practice and accompanied by official labeling, and a product sold as a research use substance bearing the same name. The two are neither identical in quality, nor equivalent in legal status, nor comparable in terms of analytical control.

What do the human clinical trials show?

The clinical record for elamipretide covers four broad areas. It is instructive precisely because it contains mixed results.

Barth syndrome. The TAZPOWER trial was a randomized, double-blind, crossover phase 2/3 study followed by an open-label extension. During the 12-week randomized phase, no significant effect was observed on the primary endpoints. Improvements on several functional and cardiac measures were, however, reported during the open-label extension. The 168-week results of that extension, published in Genetics in Medicine in 2024, involve a very small sample: ten patients entered the extension and eight reached the week 168 visit. This is a credible record for an ultra-rare disease, but it rests on a very small population and on a phase without a comparator.

Primary mitochondrial myopathy. The phase 1/2 MMPOWER trial, published in Neurology in 2018, enrolled 36 participants with genetically confirmed primary mitochondrial myopathy and produced encouraging signals. The phase 3 MMPOWER-3 trial, published in Neurology in 2023 and involving more than 200 participants randomized over 24 weeks, did not meet its primary endpoints (distance covered on the 6-minute walk test and fatigue measured by the PMMSA scale). Post hoc analyses suggest a possible effect in certain genetic subgroups, notably nuclear variants linked to the mitochondrial replisome, but a post hoc analysis generates a hypothesis, it does not validate one.

Heart failure. Daubert and colleagues published in 2017 in Circulation: Heart Failure a randomized, placebo-controlled trial evaluating a single intravenous infusion in patients with heart failure with reduced ejection fraction. A reduction in left ventricular volumes was observed at the highest dose, but the sample was small, the confidence intervals wide, and no change in biomarkers was demonstrated. The authors themselves presented this work as hypothesis-generating.

Ophthalmology. The phase 1 ReCLAIM trial, published in Ophthalmology Science in 2022 by Allingham and colleagues, was a 24-week single-center open-label study in patients with intermediate age-related macular degeneration and high-risk drusen. Its principal conclusion concerned the feasibility and tolerability of subcutaneous administration, with exploratory analyses of visual function. A phase 2 trial, ReCLAIM-2, followed in non-central geographic atrophy. An open-label phase 1 trial does not support any conclusion about efficacy.

ProgramPopulationDesignPublished result
TAZPOWERBarth syndromePhase 2/3 crossover then open-label extensionPrimary endpoints not met in the randomized phase; improvements reported in the open-label extension
MMPOWERPrimary mitochondrial myopathy (n = 36)Phase 1/2, dose escalation, controlledFavorable exploratory signals
MMPOWER-3Primary mitochondrial myopathy (more than 200 subjects)Phase 3, double-blind, 24 weeksPrimary endpoints not met
2017 HFrEF trialHeart failure with reduced EFPhase 1, single infusion, placebo-controlledReduction in ventricular volumes, small sample
ReCLAIMIntermediate AMD, high-risk drusenOpen-label phase 1, 24 weeksFeasibility and tolerability; efficacy not assessable

What do the animal and cell studies show?

The preclinical literature on SS-31 is considerably more abundant and more favorable than the clinical literature. This asymmetry is classic in pharmacology and is itself a piece of information: many molecules that perform well in rodents do not reproduce those effects in humans.

Aging muscle and heart. A study published in Aging Cell in 2025 by Mitchell and colleagues evaluated eight weeks of elamipretide treatment in aged C57BL/6J mice. The authors report an attenuation of frailty accumulation as well as improved cardiac strain and muscle fatigue resistance. An important point, often omitted in commercial summaries: no detectable change in the epigenetic or transcriptomic age of tissues was observed. The peptide improved function without shifting the biological age markers that were measured.

Kidney. Sweetwyne and colleagues published in 2017 in Kidney International a study in 24-month-old mice randomized to eight weeks of SS-31 or saline. Treatment improved age-related mitochondrial morphology and glomerulosclerosis, and reduced markers of senescence and markers of podocyte injury. A 2022 review in Oxidative Medicine and Cellular Longevity synthesizes the full set of kidney models, from ischemia-reperfusion to diabetic nephropathy.

Central nervous system. Work in aged mice has reported restoration of neurovascular coupling responses and of cerebral endothelial function, with improvement on cognitive tests. Other models have explored neurodegeneration and proteinopathy. These data are mechanistically coherent but entirely animal.

The honest reading of this body of work is as follows: SS-31 does what you would expect of a mitochondrial membrane stabilizer in tissues whose mitochondria are degraded, in animals. These are not human results, and none of these models predicts an effect in a healthy person whose mitochondrial function is not impaired.

Why is SS-31 mentioned in longevity circles?

Mitochondrial dysfunction is among the most studied hallmarks of aging. With age, oxidative capacity declines, crista morphology is altered, cardiolipin content falls and its fatty acid composition changes. A molecule that binds cardiolipin specifically and restores the organization of the inner membrane therefore fits naturally into the conversation about biological aging.

Added to that plausibility is an argument that is rare in the peptide world: the existence of a real human clinical record. The fact that elamipretide has gone through phases 1, 2 and 3, and obtained a regulatory decision in a precise indication, gives it a pharmacological credibility that compounds evaluated only in cells do not have. That credibility, however, applies to the molecule, not to the longevity application.

The animal aging data are exactly where the most rigor is needed. The 2025 Aging Cell study is often cited as proof that SS-31 "rejuvenates" tissues. What it actually shows is an improvement in functional measures in aged mice with no detectable change in epigenetic or transcriptomic clocks. Improving the function of an aged organ and slowing aging are two different claims, and only the first is supported by these data.

No controlled trial has evaluated SS-31 in healthy adults for physical performance, body composition, cognition or longevity. There is therefore no human data allowing any anti-aging benefit to be asserted. To place this peptide in the broader landscape of compounds discussed in this field, our overview of peptides studied for aging and our monograph on Epithalon offer useful points of comparison, with the same methodological caveats.

Trials under way. Three registered trials are worth following. SHAPE (NCT07275424), run at the University of Washington, is an open-label, single-arm Phase 2a pilot in about 30 adults aged 65 to 80; it has been recruiting since late 2025, and its primary aim is safety and tolerability, not efficacy. 4TAZPower (NCT07531251), sponsored by Stealth BioTherapeutics, is a randomized, placebo-controlled Phase 3b/4 trial in about 48 patients with Barth syndrome, recruiting since July 2026, after the accelerated approval. ReNEW (NCT06373731) is a placebo-controlled Phase 3 trial in dry age-related macular degeneration that has enrolled 313 participants and is no longer recruiting. None of the three has published results, and only SHAPE concerns healthy older adults, without a control group.

The summary point is this: SS-31 is mentioned in longevity circles for good mechanistic reasons and for one bad marketing reason, namely the extrapolation of trials conducted in patients with serious mitochondrial diseases to people who do not have them.

What adverse effects have been reported?

The best-documented tolerability profile comes from subcutaneous administration in clinical trials and from the official information accompanying FORZINITY. The most frequent adverse effect, by a wide margin, is injection site reactions: erythema, pain, induration, pruritus, bruising and urticaria at the administration site.

In the phase 1 ReCLAIM ophthalmology trial, every participant experienced at least one adverse event, all of mild or moderate intensity, the majority related to the injection, with no serious systemic adverse events reported. The same pattern recurs in the other programs: frequent local reactions, often bothersome but rarely serious, and a systemic profile that was broadly acceptable in the populations studied.

The U.S. product information also mentions skin reactions that may require management, as well as hypersensitivity reactions. The details of warnings, interactions and special populations belong to the official document and to a prescriber's judgment, and cannot be usefully summarized in a general article.

Two major limitations deserve emphasis. First, these tolerability data concern patients with defined conditions, followed in a clinical setting, with a pharmaceutical-grade product. They do not describe what happens outside that setting. Second, very long-term safety, beyond the durations studied, remains incompletely characterized, which is in fact consistent with the obligations attached to an accelerated approval.

For a general perspective on the risks associated with this class of molecules, including questions of purity, contamination and analytical quality, see our in-depth article on peptide safety. Anyone affected by a mitochondrial disease should discuss these points with their doctor, not with a seller.

What remains unknown about SS-31?

Despite a stronger than average record, several important areas of uncertainty remain, and identifying them is the most useful part of this guide.

Which patients actually respond. The failure of the MMPOWER-3 primary endpoints in an overall primary mitochondrial myopathy population, combined with post hoc signals in certain genotypes, suggests the effect may depend on the underlying molecular mechanism. Until a dedicated prospective trial has confirmed this hypothesis in the relevant subgroup, it remains a hypothesis.

The link between biomarker and clinical benefit. Many favorable results concern surrogate measures: mitochondrial morphology, oxidative capacity, the strength of one muscle group, ventricular volumes. Translating these measures into durable benefits for daily function, quality of life or survival has not been definitively demonstrated, and that is precisely what the confirmation attached to the accelerated approval must establish.

Effects in healthy subjects. Several studies suggest the peptide has little effect on mitochondria that already function well. If that holds true in humans, the interest for a healthy person would be limited. No study currently settles the question.

Duration of exposure and reversibility. It is unknown what happens after prolonged exposure stops, whether any effect persists, and whether very long administration alters mitochondrial homeostasis in some unanticipated way. Cardiolipin biology is intertwined with apoptosis and mitophagy, two processes whose chronic modulation is not a trivial matter.

Route and form of administration. The human data rest on parenteral administration carried out in a clinical setting. No oral form has been validated, and peptides of this type are as a rule degraded in the digestive tract. The alternative presentations offered outside the pharmaceutical channel have no published efficacy data behind them.

How does it compare with MOTS-c and NAD+?

SS-31 is often filed in the same category as other so-called mitochondrial approaches. The mechanisms are nevertheless very different, and the level of evidence even more so.

MOTS-c is a peptide derived from mitochondrial DNA, encoded within the 16S ribosomal RNA gene. It acts as a signaling molecule that influences metabolism, notably via pathways involving AMPK, and its action largely concerns the cell nucleus and metabolic regulation. SS-31, by contrast, is not an endogenous signaling molecule: it is a synthetic compound that acts physically on a membrane. In terms of evidence, MOTS-c rests essentially on preclinical work and observational data, without a clinical program comparable to that of elamipretide.

NAD+ strategies form a third category. They do not target a membrane structure but the availability of a central cofactor of redox metabolism, generally via precursors. Human trials have shown that NAD+ concentrations can be raised in certain tissues, but translating that rise into clinically meaningful functional benefits remains inconsistent across studies and populations.

ApproachNatureMain targetLevel of human evidence
SS-31 / elamipretideSynthetic tetrapeptideCardiolipin of the inner mitochondrial membranePublished phase 1 to 3 trials; FDA accelerated approval in a rare indication
MOTS-cPeptide derived from mitochondrial DNAMetabolic signaling, AMPK pathwaysEssentially preclinical
NAD+ precursorsSmall moleculesAvailability of the NAD+ cofactorSmall human trials, inconsistent functional results

No published data evaluate combining these approaches with one another in humans. Reasoning of the "complementary mechanisms, therefore beneficial combination" type is speculation, not evidence.

How should you read the available information on SS-31?

SS-31 sits in an unusual position: it is at once a pharmaceutical molecule approved in a precise indication and a name widely used in the trade of research use substances. That ambiguity is the main source of confusion for readers.

Three reading habits help in navigating it. First, check whether a claim concerns humans or animals, because the preclinical literature dominates in sheer numbers. Second, check whether a human trial was randomized and controlled, or open-label and without a comparator: improvements observed in an open-label extension do not read the same way as those from a randomized phase. Third, distinguish a prespecified analysis from a post hoc analysis.

On the practical side, peptides are fragile molecules, sensitive to temperature, light and freeze-thaw cycles. Our peptide storage guide details the general stability principles that apply to this class of compounds.

If your question concerns the quantitative rather than the scientific aspects, it is handled separately: see our SS-31 calculator.

We do not offer any SS-31 product and do not refer readers to any supplier for this molecule. To organize your reading, follow the publications that interest you and find our monographs, the Peptide Lab app is available free of charge.

Important reminder. This article is educational in purpose. SS-31 (elamipretide) is approved only in a rare and strictly defined indication; any other use falls outside the framework assessed by the authorities. Legal status varies by jurisdiction. Consult a healthcare professional before making any decision about your health.

Test your knowledge

Quick quiz · 6 questions

Frequently asked questions

Are SS-31 and elamipretide the same molecule?
Yes. SS-31 is the designation that came out of academic research, derived from the initials of researchers Szeto and Schiller. Elamipretide is the international nonproprietary name adopted for pharmaceutical development. The molecule has also carried the code names MTP-131 and Bendavia, and it is marketed in the United States under the name FORZINITY in its approved indication. It is the same tetrapeptide, with the sequence D-Arg-Dmt-Lys-Phe-NH₂ and a molecular weight of 639.80 g/mol. In practice, the names used often signal the context: SS-31 points more to the preclinical literature and the research market, elamipretide to the clinical and regulatory setting.
Is SS-31 approved by the FDA?
Partly, and within a very precise framework. On September 19, 2025, the FDA granted accelerated approval to elamipretide under the name FORZINITY, to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. That approval rests on a surrogate endpoint, improvement in knee extensor strength, and keeping it depends on later confirmation of clinical benefit. It covers no other indication, nor use in healthy people. No equivalent European authorization could be documented at the time of writing.
Is SS-31 simply an antioxidant?
That description is now considered incomplete. Early work described the peptide as a mitochondria-targeted scavenger of reactive oxygen species. Later research, notably that of Birk and colleagues in 2013 and then more recent biophysical analyses, showed that its main action consists of associating with cardiolipin in the inner mitochondrial membrane and altering that membrane's surface electrostatic potential. The reduction in oxidative stress observed would largely be a consequence of better coupling of the respiratory chain, rather than the molecule's primary effect. This distinction matters, because it explains why SS-31 does not behave like a classic dietary antioxidant.
Does SS-31 improve athletic performance or muscle mass?
No published data support that claim. The human trials were conducted in patients with mitochondrial diseases, heart failure or retinal conditions, that is, populations whose mitochondrial function is impaired. The improvements in strength and fatigue resistance reported in the literature concern aged mice or patients with a defined disease. Several studies also suggest that the peptide has little effect on mitochondria that already function well, which would make a benefit in a healthy, trained person unlikely, though this has not been tested directly.
Does SS-31 exist in an oral form?
All published clinical data rest on parenteral administration, mainly subcutaneous and, in one cardiology trial, by intravenous infusion. No oral form has been validated in a published clinical trial. Like most peptides, SS-31 is in principle degraded by digestive peptidases and absorbed only to a very limited extent by the enteral route, even though its non-natural amino acids make it more stable than average in blood. The alternative presentations offered outside the pharmaceutical channel are not supported by any published efficacy data.
What is the difference between SS-31 and MOTS-c?
Both are described as mitochondrial peptides, but their nature and mechanism differ fundamentally. MOTS-c is an endogenous peptide encoded by mitochondrial DNA that acts as a metabolic signaling molecule, with effects described notably on AMPK pathways and on the regulation of nuclear gene expression. SS-31 is a synthetic compound that acts physically at the level of the inner mitochondrial membrane by associating with cardiolipin. The most important difference concerns the level of evidence: SS-31 has published phase 1 to 3 human trials and a regulatory decision, whereas MOTS-c rests essentially on preclinical data. Our MOTS-c monograph covers that work in detail.
Does SS-31 slow biological aging?
The available data do not allow that claim. The most directly relevant study, published in Aging Cell in 2025, evaluated eight weeks of treatment in aged mice: the authors report an attenuation of frailty, improved cardiac strain and better muscle fatigue resistance, but explicitly no detectable change in the epigenetic or transcriptomic age of tissues. In other words, function improved without the biological clocks that were measured shifting. No human trial has evaluated SS-31 for longevity, so there is no clinical data to support an anti-aging claim.
What adverse effects have been reported in the trials?
Injection site reactions are the most frequent adverse effect with subcutaneous administration: erythema, pain, induration, pruritus, bruising and urticaria at the administration site. In the phase 1 ReCLAIM ophthalmology trial, every participant reported at least one adverse event, all of mild or moderate intensity, mostly related to the injection, with no serious systemic events. The U.S. product information also mentions skin reactions that may require management and hypersensitivity reactions. These data come from patients followed in a clinical setting with a pharmaceutical-grade product, and very long-term tolerability remains incompletely characterized. Any individual question is a matter for a healthcare professional.

Scientific sources

  1. Birk AV, Liu S, Soong Y, et al. (2013). The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology. (PubMed)
  2. Sabbah HN, Alder NN, Sparagna GC, et al. (2025). Contemporary insights into elamipretide's mitochondrial mechanism of action and therapeutic effects. Biomedicine & Pharmacotherapy. (PMC)
  3. Reid Thompson W, Hornby B, Steele H, et al. (2024). Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER. Genetics in Medicine. (PubMed)
  4. Karaa A, Haas R, Goldstein A, et al. (2018). Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. (PubMed)
  5. Karaa A, Bertini E, Carelli V, et al. (2023). Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. Neurology. (PMC)
  6. Allingham MJ, Mettu PS, Cousins SW (2022). Phase 1 Clinical Trial of Elamipretide in Intermediate Age-Related Macular Degeneration and High-Risk Drusen: ReCLAIM High-Risk Drusen Study. Ophthalmology Science. (PubMed)
  7. Mitchell W, Pharaoh G, Tyshkovskiy A, Campbell M, Marcinek DJ, Gladyshev VN (2025). The Mitochondria-Targeted Peptide Therapeutic Elamipretide Improves Cardiac and Skeletal Muscle Function During Aging Without Detectable Changes in Tissue Epigenetic or Transcriptomic Age. Aging Cell. (PubMed)
  8. Sweetwyne MT, Pippin JW, Eng DG, et al. (2017). The mitochondrial-targeted peptide, SS-31, improves glomerular architecture in mice of advanced age. Kidney International. (PubMed)
  9. Zhu Y, Luo M, Bai X, et al. (2022). SS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney Disease. Oxidative Medicine and Cellular Longevity. (PMC)
  10. U.S. Food and Drug Administration (2025). FORZINITY (elamipretide) prescribing information, NDA 215244, accelerated approval. FDA Drugs@FDA. (accessdata.fda.gov)
  11. Daubert MA, Yow E, Dunn G, et al. (2017). Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide. Circulation: Heart Failure. (PubMed)
  12. University of Washington (Marcinek D) (2025). Study of Healthy Aging and Physical Function With Elamipretide (SHAPE): open-label, single-arm Phase 2a pilot study in older adults (NCT07275424). ClinicalTrials.gov. (clinicaltrials.gov)
  13. Stealth BioTherapeutics (2026). Phase 3b/4, randomized, double-blind, placebo-controlled trial of elamipretide in patients with genetically confirmed Barth syndrome (4TAZPower, NCT07531251). ClinicalTrials.gov. (clinicaltrials.gov)
  14. Stealth BioTherapeutics (2024). ReNEW: Phase 3, double-masked, placebo-controlled trial of subcutaneous elamipretide in dry age-related macular degeneration (NCT06373731). ClinicalTrials.gov. (clinicaltrials.gov)

This content is for informational and educational purposes only. It does not constitute medical advice. Consult a healthcare professional before making any decisions. Read our full medical disclaimer

GHK-Cu
GHK-Cu
Powerful Anti-Aging →